PT1933833E - Terapia para o tratamento da bexiga superactiva - Google Patents

Terapia para o tratamento da bexiga superactiva Download PDF

Info

Publication number
PT1933833E
PT1933833E PT06813885T PT06813885T PT1933833E PT 1933833 E PT1933833 E PT 1933833E PT 06813885 T PT06813885 T PT 06813885T PT 06813885 T PT06813885 T PT 06813885T PT 1933833 E PT1933833 E PT 1933833E
Authority
PT
Portugal
Prior art keywords
overactive bladder
therapy
treatment
disclosed
pharmaceutically acceptable
Prior art date
Application number
PT06813885T
Other languages
English (en)
Inventor
Mehdi Paborji
Original Assignee
Theravida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravida Inc filed Critical Theravida Inc
Publication of PT1933833E publication Critical patent/PT1933833E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
PT06813885T 2005-09-02 2006-08-28 Terapia para o tratamento da bexiga superactiva PT1933833E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71415005P 2005-09-02 2005-09-02

Publications (1)

Publication Number Publication Date
PT1933833E true PT1933833E (pt) 2011-07-08

Family

ID=37502599

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06813885T PT1933833E (pt) 2005-09-02 2006-08-28 Terapia para o tratamento da bexiga superactiva

Country Status (19)

Country Link
US (6) US7678821B2 (pt)
EP (1) EP1933833B8 (pt)
JP (1) JP5312027B2 (pt)
KR (1) KR101054248B1 (pt)
CN (2) CN103142586A (pt)
AT (1) ATE506059T1 (pt)
AU (1) AU2006284940B2 (pt)
BR (1) BRPI0615432A2 (pt)
CA (1) CA2619565C (pt)
DE (1) DE602006021444D1 (pt)
DK (1) DK1933833T3 (pt)
ES (1) ES2365161T3 (pt)
IL (1) IL189546A (pt)
NZ (1) NZ565840A (pt)
PL (1) PL1933833T3 (pt)
PT (1) PT1933833E (pt)
RU (1) RU2435610C2 (pt)
WO (1) WO2007027675A1 (pt)
ZA (1) ZA200802811B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2619565C (en) * 2005-09-02 2015-06-23 Theravida, Inc. Therapy for the treatment of disease
JP5637551B2 (ja) * 2005-12-28 2014-12-10 キッセイ薬品工業株式会社 唾液腺障害の治療用医薬
US20100297225A1 (en) * 2007-12-20 2010-11-25 Pharmathen S.A. Sustained-release pharmaceutical formulation containing an antimuscarinic agent and a wetting agent as well as a process for the preparation thereof
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
DK3061821T3 (da) * 2009-07-22 2019-08-26 PureTech Health LLC Sammensætninger til behandling af forstyrrelser lindret af muskarinreceptoraktivering
GB2479213B (en) * 2010-04-01 2013-07-10 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
KR20130065650A (ko) * 2010-04-01 2013-06-19 테라비다, 인코포레이티드 수면의 질 개선 방법
KR20130092545A (ko) * 2010-05-12 2013-08-20 심보미 체질에 따라 다른 변비개선용 천연식품 조성물
CN103179926A (zh) * 2010-06-22 2013-06-26 特卫华妇女健康有限公司 包含抗胆碱剂的阴道内装置及其制备方法
US9119878B2 (en) 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
KR101932714B1 (ko) * 2010-09-28 2018-12-26 삼성전자주식회사 소셜 그룹 생성 및 연결 방법, 그 방법을 수행할 수 있는 유저 디바이스, 서버 및 저장 매체
WO2012154770A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
US20120289564A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of oxybutynin and salivary stimulants for the treatment of overactive bladder
US20120289561A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of fesoterodine and salivary stimulants for the treatment of overactive bladder
JP2014513689A (ja) * 2011-05-10 2014-06-05 セラヴィダ，インコーポレイテッド 過活動膀胱の治療のためのトロスピウムと唾液分泌刺激剤の組合せ
WO2012154775A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder
WO2012154892A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of propiverine and salivary stimulants for the treatment of overactive bladder
US20120289563A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of imidafenacin and salivary stimulants for the treatment of overactive bladder
AU2012253667B2 (en) * 2011-05-10 2017-06-01 Theravida, Inc. Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
NZ630471A (en) * 2012-03-19 2016-04-29 Wellesley Pharmaceuticals Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
EP3216446A1 (en) * 2012-05-01 2017-09-13 TheraVida, Inc. Methods for the treatment of overactive bladder
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
US20170361091A1 (en) * 2014-12-23 2017-12-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Devices, Systems and Methods for Treating Urological and Gastrointestinal Disorders by Electrical Stimulation of the Foot
EP3265128A4 (en) * 2015-03-06 2018-09-12 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system muscarinic agonist combination
AU2016388308B2 (en) * 2016-01-20 2022-08-04 Theravida, Inc. Methods and compositions for treating hyperhidrosis
EP3681500B1 (en) 2018-04-24 2022-03-23 Allergan, Inc. Use of pilocarpine hydrochloride for the treatment of presbyopia
CN115581696A (zh) 2018-09-28 2023-01-10 卡鲁娜治疗学有限公司 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
EP3967311A1 (en) 2020-09-11 2022-03-16 Astellas Pharma Inc. Compounds for use in the treatment of dry mouth
US11564909B2 (en) 2020-11-30 2023-01-31 Romeg Therapeutics Llc Methods and compositions for oral pilocarpine liquid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
TR200001828T2 (tr) * 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem.
ES2415876T3 (es) * 1997-12-22 2013-07-29 Euro-Celtique S.A. Forma de dosificación farmacéutica oral que comprende una combinación de un agonista de opiáceos y un antagonista de opiáceos
US6482837B1 (en) * 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
WO2001054728A1 (en) * 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha NOVEL REMEDIES WITH THE USE OF β3 AGONIST
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
WO2006132196A1 (ja) * 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation β３作動薬を含有する新規な医薬
CA2619565C (en) * 2005-09-02 2015-06-23 Theravida, Inc. Therapy for the treatment of disease

Also Published As

Publication number Publication date
RU2435610C2 (ru) 2011-12-10
RU2008112687A (ru) 2009-10-10
CA2619565A1 (en) 2007-03-08
BRPI0615432A2 (pt) 2011-05-17
JP5312027B2 (ja) 2013-10-09
DE602006021444D1 (de) 2011-06-01
DK1933833T3 (da) 2011-07-25
US20090318522A1 (en) 2009-12-24
PL1933833T3 (pl) 2011-09-30
EP1933833B8 (en) 2011-09-14
US8470864B2 (en) 2013-06-25
US20130289087A1 (en) 2013-10-31
IL189546A (en) 2014-08-31
US20100137392A1 (en) 2010-06-03
EP1933833A1 (en) 2008-06-25
US7781472B2 (en) 2010-08-24
EP1933833B1 (en) 2011-04-20
US7666894B2 (en) 2010-02-23
IL189546A0 (en) 2008-08-07
ZA200802811B (en) 2009-09-30
AU2006284940B2 (en) 2012-03-22
CN101287462A (zh) 2008-10-15
ES2365161T3 (es) 2011-09-23
CN103142586A (zh) 2013-06-12
JP2009507021A (ja) 2009-02-19
KR101054248B1 (ko) 2011-08-08
US20090275629A1 (en) 2009-11-05
WO2007027675A1 (en) 2007-03-08
CA2619565C (en) 2015-06-23
US20070053995A1 (en) 2007-03-08
US7678821B2 (en) 2010-03-16
ATE506059T1 (de) 2011-05-15
KR20080059155A (ko) 2008-06-26
AU2006284940A1 (en) 2007-03-08
US20100152263A1 (en) 2010-06-17
NZ565840A (en) 2011-07-29

Similar Documents

Publication Publication Date Title
PT1933833E (pt) Terapia para o tratamento da bexiga superactiva
AU2018256546A1 (en) Combination therapy with peptide epoxyketones
HK1120441A1 (en) Drugs for treatment of ovarian cancer
MY148108A (en) Medicaments for the treatment or prevention of fibrotic diseases
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
WO2006034373A3 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
NZ602675A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
NO20063716L (no) Anvendelse av lavdose erytropoietin ved stimulering av endotel forloperceller, regenerering av organer og sinking av progresjonen av sluttorganskader
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
CA2464758A1 (en) Combination therapy comprising zd6474 and a taxane
NZ592615A (en) Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
RS20080497A (en) Novel low dose pharmaceutical compositions comrising nimesulide, preparation and use thereof
TW200637544A (en) Medicaments for the treatment or prevention of fibrotic diseases
MX2022000143A (es) Metodos novedosos.
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
NZ592613A (en) Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
MX2012002161A (es) El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento de cancer.
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega